Compare Stocks: CTXR, HRTX, TLPH, and RFL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.55 -2.1%	$0.53	$0.37 ▼ $1.54	$15.10M	1	537,417 shs	11,309 shs
HRTX Heron Therapeutics	$0.29 -1.4%	$0.33	$0.26 ▼ $1.58	$56.01M	1.65	2.47 million shs	240,814 shs
RFL Rafael	$1.08 +7.6%	$1.82	$0.99 ▼ $3.96	$55.95M	0.35	134,105 shs	60,182 shs
TLPH Talphera	$1.04 +2.5%	$1.14	$0.69 ▼ $1.57	$53.73M	0.67	223,260 shs	35,830 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	+7.44%	+25.08%	+5.72%	-9.72%	-64.43%
HRTX Heron Therapeutics	+6.27%	-1.86%	-15.10%	-42.31%	-74.56%
RFL Rafael	-7.76%	-14.19%	-34.03%	-46.95%	-25.90%
TLPH Talphera	-1.94%	-5.61%	-10.62%	-25.74%	-24.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.55 -2.1%	$0.53	$0.37 ▼ $1.54	$15.10M	1	537,417 shs	11,309 shs
HRTX Heron Therapeutics	$0.29 -1.4%	$0.33	$0.26 ▼ $1.58	$56.01M	1.65	2.47 million shs	240,814 shs
RFL Rafael	$1.08 +7.6%	$1.82	$0.99 ▼ $3.96	$55.95M	0.35	134,105 shs	60,182 shs
TLPH Talphera	$1.04 +2.5%	$1.14	$0.69 ▼ $1.57	$53.73M	0.67	223,260 shs	35,830 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	+7.44%	+25.08%	+5.72%	-9.72%	-64.43%
HRTX Heron Therapeutics	+6.27%	-1.86%	-15.10%	-42.31%	-74.56%
RFL Rafael	-7.76%	-14.19%	-34.03%	-46.95%	-25.90%
TLPH Talphera	-1.94%	-5.61%	-10.62%	-25.74%	-24.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.40	Hold	$6.00	990.91% Upside
HRTX Heron Therapeutics	2.00	Hold	$2.00	587.29% Upside
RFL Rafael	1.00	Sell	N/A	N/A
TLPH Talphera	2.25	Hold	$3.00	189.86% Upside

Current Analyst Ratings Breakdown

Latest CTXR, HRTX, TLPH, and RFL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/15/2026	TLPH Talphera	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/25/2026	RFL Rafael	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/13/2026	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$3.00
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
HRTX Heron Therapeutics	$151.18M	0.37	N/A	N/A	$0.07 per share	4.16
RFL Rafael	$874K	64.02	N/A	N/A	$1.91 per share	0.56
TLPH Talphera	$30K	1,790.90	N/A	N/A	$0.37 per share	2.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	12/29/2026 (Estimated)
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/9/2026 (Estimated)
RFL Rafael	-$30.52M	-$0.58	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	12/10/2026 (Estimated)
TLPH Talphera	-$14.29M	-$0.27	N/A	N/A	N/A	N/A	-87.28%	-51.36%	11/11/2026 (Estimated)

Latest CTXR, HRTX, TLPH, and RFL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	TLPH Talphera	-$0.06	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	HRTX Heron Therapeutics	-$0.03	N/A	N/A	N/A	$37.50 million	N/A
10/29/2026	Q4 2026	RFL Rafael	N/A	-$0.18	N/A	-$0.18	N/A	$0.24 million
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/13/2026	Q2 2026	TLPH Talphera	-$0.0625	-$0.06	+$0.0025	-$0.06	N/A	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
HRTX Heron Therapeutics	24.35	2.49	1.51
RFL Rafael	N/A	3.16	3.14
TLPH Talphera	N/A	4.29	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
HRTX Heron Therapeutics	80.01%
RFL Rafael	11.30%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	4.99%
HRTX Heron Therapeutics	6.10%
RFL Rafael	32.90%
TLPH Talphera	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	23	27.45 million	26.08 million	Optionable
HRTX Heron Therapeutics	128	189.85 million	178.27 million	Optionable
RFL Rafael	23	52.00 million	34.89 million	Optionable
TLPH Talphera	12	51.91 million	50.09 million	Optionable

CTXR, HRTX, TLPH, and RFL Headlines

Recent News About These Companies

Talphera (TLPH) Stock Forecast & Price Target

September 30, 2026 | investing.com

Talphera (TLPH) upgraded to buy: Here's what you should know

September 21, 2026 | msn.com

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026 | prnewswire.com

Talphera Earnings Call Highlights Nafamostat Momentum

August 23, 2026 | tipranks.com

Talphera (TLPH) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Talphera, Inc. (TLPH) Q2 FY2026 earnings call transcript

August 14, 2026 | finance.yahoo.com

Talphera, Inc. (TLPH) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ...

August 13, 2026 | uk.finance.yahoo.com

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

August 13, 2026 | seekingalpha.com

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | aol.comA

Talphera Q2 2026 earnings preview

August 11, 2026 | msn.com

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

August 5, 2026 | prnewswire.com

Talphera, Inc. Common Stock

July 15, 2026 | fxempire.comF

Talphera (TLPH) CEO Angotti buys $85k in shares

May 21, 2026 | investing.com

Talphera Earnings Call Highlights NEPHRO Trial Momentum

May 19, 2026 | tipranks.com

Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...

May 15, 2026 | finance.yahoo.com

Talphera Earnings Call Highlights Trial Momentum, Risks

May 14, 2026 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026 | finanznachrichten.de

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, HRTX, TLPH, and RFL Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$0.55 -0.01 (-2.14%)

As of 11:34 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Heron Therapeutics NASDAQ:HRTX

$0.29 0.00 (-1.39%)

As of 11:34 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Rafael NYSE:RFL

$1.08 +0.08 (+7.60%)

As of 11:29 AM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Talphera NASDAQ:TLPH

$1.03 +0.03 (+2.48%)

As of 11:32 AM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTXR, HRTX, TLPH, and RFL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTXR, HRTX, TLPH, and RFL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTXR, HRTX, TLPH, and RFL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, HRTX, TLPH, and RFL Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Heron Therapeutics NASDAQ:HRTX

Rafael NYSE:RFL

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTXR, HRTX, TLPH, and RFL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTXR, HRTX, TLPH, and RFL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTXR, HRTX, TLPH, and RFL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, HRTX, TLPH, and RFL Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Heron Therapeutics NASDAQ:HRTX

Rafael NYSE:RFL

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools